Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal ...

Mainz Biomed’s stool-based ColoAlert test is designed to detect colorectal ... “We are excited by the opportunity to work with Quest Diagnostics,” commented Guido Baechler, Chief Executive ...

announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz Biomed’s NextGen screening test for ...

announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz Biomed’s NextGen screening test for ...

Patients with inflammatory bowel disease (IBD) reported mostly favorable responses with the use of mail-order kits for stool ...

Older adults on Medicare Advantage had improved adherence and odds of a test return when a stool test was mailed to them for screening of colorectal cancer (CRC). Improving outcomes in CRC ...

Opens in a new tab or window ORLANDO -- Patients with inflammatory bowel disease (IBD) reported mostly favorable responses with the use of mail-order kits for stool sample collections, according ...